Modulation of CXCL14 (BRAK) expression in prostate cancer

Steven R. Schwarze, Jun Luo, William B Isaacs, David F. Jarrard

Research output: Contribution to journalArticle

Abstract

BACKGROUND. Recent studies suggest inflammatory processes may be involved in the development or progression of prostate cancer. Chemokines are a family of cytokines that can play several roles in cancer progression including angiogenesis, inflammation, cell recruitment, and migration. METHODS. Real-time quantitative RT-PCR, in situ RNA hybridization, laser capture microscopy, immunohistochemistry, and cDNA array based technologies were used to examine CXCL14 (BRAK) expression in paired normal and tumor prostate. To determine the role CXCL14 expression has on cancer progression, LAPC4 cells were engineered to overexpress mouse or human CXCL14, and xenograft studies were performed. RESULTS. CXCL14 RNA expression was observed in normal and tumor prostate epithelium and focally in stromal cells adjacent to cancer. CXCL14 mRNA was significantly upregulated in localized prostate cancer and positively correlated with Gleason score. CXCL14 levels were unchanged in BPH specimens. LAPC4 cells expressing CXCL14 resulted in a 43% tumor growth inhibition (P = 0.019) in vivo compared to vector only xenografts. CONCLUSIONS. CXCL14 mRNA upregulation is a common feature in prostate cancer. The finding that CXCL14 expression inhibits tumor growth suggests this gene has tumor suppressive functions.

Original languageEnglish (US)
Pages (from-to)67-74
Number of pages8
JournalProstate
Volume64
Issue number1
DOIs
StatePublished - Jun 15 2005

Fingerprint

Prostatic Neoplasms
Neoplasms
Heterografts
Prostate
RNA
Messenger RNA
Neoplasm Grading
Stromal Cells
Growth
Oligonucleotide Array Sequence Analysis
Chemokines
Confocal Microscopy
Cell Movement
In Situ Hybridization
Real-Time Polymerase Chain Reaction
Up-Regulation
Epithelium
Immunohistochemistry
Cytokines
Inflammation

Keywords

  • Cancer
  • Chemokine
  • Inflammation
  • Xenograft

ASJC Scopus subject areas

  • Urology

Cite this

Modulation of CXCL14 (BRAK) expression in prostate cancer. / Schwarze, Steven R.; Luo, Jun; Isaacs, William B; Jarrard, David F.

In: Prostate, Vol. 64, No. 1, 15.06.2005, p. 67-74.

Research output: Contribution to journalArticle

Schwarze, Steven R. ; Luo, Jun ; Isaacs, William B ; Jarrard, David F. / Modulation of CXCL14 (BRAK) expression in prostate cancer. In: Prostate. 2005 ; Vol. 64, No. 1. pp. 67-74.
@article{4c90de7e5be3442ca3b7a01c27f99d97,
title = "Modulation of CXCL14 (BRAK) expression in prostate cancer",
abstract = "BACKGROUND. Recent studies suggest inflammatory processes may be involved in the development or progression of prostate cancer. Chemokines are a family of cytokines that can play several roles in cancer progression including angiogenesis, inflammation, cell recruitment, and migration. METHODS. Real-time quantitative RT-PCR, in situ RNA hybridization, laser capture microscopy, immunohistochemistry, and cDNA array based technologies were used to examine CXCL14 (BRAK) expression in paired normal and tumor prostate. To determine the role CXCL14 expression has on cancer progression, LAPC4 cells were engineered to overexpress mouse or human CXCL14, and xenograft studies were performed. RESULTS. CXCL14 RNA expression was observed in normal and tumor prostate epithelium and focally in stromal cells adjacent to cancer. CXCL14 mRNA was significantly upregulated in localized prostate cancer and positively correlated with Gleason score. CXCL14 levels were unchanged in BPH specimens. LAPC4 cells expressing CXCL14 resulted in a 43{\%} tumor growth inhibition (P = 0.019) in vivo compared to vector only xenografts. CONCLUSIONS. CXCL14 mRNA upregulation is a common feature in prostate cancer. The finding that CXCL14 expression inhibits tumor growth suggests this gene has tumor suppressive functions.",
keywords = "Cancer, Chemokine, Inflammation, Xenograft",
author = "Schwarze, {Steven R.} and Jun Luo and Isaacs, {William B} and Jarrard, {David F.}",
year = "2005",
month = "6",
day = "15",
doi = "10.1002/pros.20215",
language = "English (US)",
volume = "64",
pages = "67--74",
journal = "Prostate",
issn = "0270-4137",
publisher = "Wiley-Liss Inc.",
number = "1",

}

TY - JOUR

T1 - Modulation of CXCL14 (BRAK) expression in prostate cancer

AU - Schwarze, Steven R.

AU - Luo, Jun

AU - Isaacs, William B

AU - Jarrard, David F.

PY - 2005/6/15

Y1 - 2005/6/15

N2 - BACKGROUND. Recent studies suggest inflammatory processes may be involved in the development or progression of prostate cancer. Chemokines are a family of cytokines that can play several roles in cancer progression including angiogenesis, inflammation, cell recruitment, and migration. METHODS. Real-time quantitative RT-PCR, in situ RNA hybridization, laser capture microscopy, immunohistochemistry, and cDNA array based technologies were used to examine CXCL14 (BRAK) expression in paired normal and tumor prostate. To determine the role CXCL14 expression has on cancer progression, LAPC4 cells were engineered to overexpress mouse or human CXCL14, and xenograft studies were performed. RESULTS. CXCL14 RNA expression was observed in normal and tumor prostate epithelium and focally in stromal cells adjacent to cancer. CXCL14 mRNA was significantly upregulated in localized prostate cancer and positively correlated with Gleason score. CXCL14 levels were unchanged in BPH specimens. LAPC4 cells expressing CXCL14 resulted in a 43% tumor growth inhibition (P = 0.019) in vivo compared to vector only xenografts. CONCLUSIONS. CXCL14 mRNA upregulation is a common feature in prostate cancer. The finding that CXCL14 expression inhibits tumor growth suggests this gene has tumor suppressive functions.

AB - BACKGROUND. Recent studies suggest inflammatory processes may be involved in the development or progression of prostate cancer. Chemokines are a family of cytokines that can play several roles in cancer progression including angiogenesis, inflammation, cell recruitment, and migration. METHODS. Real-time quantitative RT-PCR, in situ RNA hybridization, laser capture microscopy, immunohistochemistry, and cDNA array based technologies were used to examine CXCL14 (BRAK) expression in paired normal and tumor prostate. To determine the role CXCL14 expression has on cancer progression, LAPC4 cells were engineered to overexpress mouse or human CXCL14, and xenograft studies were performed. RESULTS. CXCL14 RNA expression was observed in normal and tumor prostate epithelium and focally in stromal cells adjacent to cancer. CXCL14 mRNA was significantly upregulated in localized prostate cancer and positively correlated with Gleason score. CXCL14 levels were unchanged in BPH specimens. LAPC4 cells expressing CXCL14 resulted in a 43% tumor growth inhibition (P = 0.019) in vivo compared to vector only xenografts. CONCLUSIONS. CXCL14 mRNA upregulation is a common feature in prostate cancer. The finding that CXCL14 expression inhibits tumor growth suggests this gene has tumor suppressive functions.

KW - Cancer

KW - Chemokine

KW - Inflammation

KW - Xenograft

UR - http://www.scopus.com/inward/record.url?scp=19544380723&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=19544380723&partnerID=8YFLogxK

U2 - 10.1002/pros.20215

DO - 10.1002/pros.20215

M3 - Article

VL - 64

SP - 67

EP - 74

JO - Prostate

JF - Prostate

SN - 0270-4137

IS - 1

ER -